Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Runben Biotechnology Co's Revenue for the
three
months ended in Jun. 2026 was ¥787 Mil. Runben Biotechnology Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was ¥58 Mil.
Hence, Runben Biotechnology Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 13.64.
Runben Biotechnology Co (SHSE:603193) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Runben Biotechnology Co Receivables Turnover Related Terms
Runben Biotechnology Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Runben Biotechnology Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Runben Biotechnology Co Receivables Turnover Chart
SHSE:603193 vs PG, CL, EL: Receivables Turnover Comparison
For the Household & Personal Products subindustry, Runben Biotechnology Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Runben Biotechnology Co Receivables Turnover vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Runben Biotechnology Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Runben Biotechnology Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Runben Biotechnology Co (SHSE:603193) has a Receivables Turnover of 13.64 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Runben Biotechnology Co and its competitors. According to the industry distribution chart, Runben Biotechnology Co ranks #205 out of 1949 companies in the Consumer Packaged Goods industry, placing it in the top 10.5%.
Is Runben Biotechnology Co's Receivables Turnover too high?
Runben Biotechnology Co's current Receivables Turnover is 13.64. The Consumer Packaged Goods industry median Receivables Turnover is 9.45. Runben Biotechnology Co's value of 13.64 is 44.3% above this industry median. Based on the distribution chart, Runben Biotechnology Co ranks #205 out of 1949 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Runben Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Runben Biotechnology Co's Receivables Turnover compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Runben Biotechnology Co ranks #205 out of 1949 companies for Receivables Turnover. This places Runben Biotechnology Co in the top 11% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 9.45. Runben Biotechnology Co's value of 13.64 is 44.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Consumer Packaged Goods company?
The median Receivables Turnover among Consumer Packaged Goods companies is 9.45, based on 1,949 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Runben Biotechnology Co's current Receivables Turnover of 13.64 is 44.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Runben Biotechnology Co and its competitors. For the Consumer Packaged Goods industry, the median Receivables Turnover is 9.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Runben Biotechnology Co's current Receivables Turnover is 13.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Runben Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.71, compared to a current price of ¥21.84 — trading 23.9% below its estimated fair value. The current Receivables Turnover is 13.64 and 44.3% above the Consumer Packaged Goods industry median of 9.45. Runben Biotechnology Co's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current Receivables Turnover is 13.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?
Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued.
The current stock price of ¥21.84 is trading 23.9% below its estimated GF Value™ of ¥28.71.
GuruFocus considers Runben Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:603193:
Receivables Turnover: 13.64
GF Value™: ¥28.71 vs. price of ¥21.84 (23.9% below fair value)
Industry Position: 44.3% above the Consumer Packaged Goods median (#205 of 1949)
No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603193 has been successfully added to your 
